Syncona Limited Release of Key Information Document

 
TIDMSYNC 
 
Syncona Limited 
 
                      Release of Key Information Document 
 
02 January 2017 
 
Syncona Ltd ("Syncona"), a leading healthcare company focused on investing in 
and building global leaders in life science, has released a Key Information 
Document ("KID") in compliance with the Packaged Retail and Insurance-based 
Investment Products ("PRIIPs") Regulation that comes into effect in January 
2018. 
 
The KID is available on the Company's website in the Investor Relations 
section. 
 
[ENDS] 
 
Enquiries 
 
Syncona Ltd 
Siobhan Weaver 
Tel: [phone] 
 
Copies of this press release and other corporate information can be found on 
the company website at: www.synconaltd.com 
 
Forward-looking statements - this announcement contains certain forward-looking 
statements with respect to the portfolio of investments of Syncona Ltd. These 
statements and forecasts involve risk and uncertainty because they relate to 
events and depend upon circumstances that may or may not occur in the future. 
There are a number of factors that could cause actual results or developments 
to differ materially from those expressed or implied by these forward-looking 
statements and forecasts. Nothing in this announcement should be construed as a 
profit forecast. 
 
About Syncona: 
 
Syncona is a leading FTSE250 healthcare company focused on investing in and 
building global leaders in life science. Our vision is to deliver 
transformational treatments to patients in truly innovative areas of healthcare 
while generating superior returns for shareholders. Our current investment 
portfolio consists of seven high quality companies in life science and a 
leading range of fund investments.  We seek to partner with the best, brightest 
and most ambitious minds in science to build globally competitive businesses. 
We are established leaders in gene therapy, cell therapy and advanced 
diagnostics, and focus on delivering dramatic efficacy for patients in areas of 
high unmet need. 
 
Our market leading funds portfolio seeks to generate superior returns by 
investing in long only and alternative investment funds. This represents a 
productively deployed evergreen funding base which enables us to take a long 
term approach to investing in life sciences as we target the best new 
opportunities and support our existing portfolio companies to grow and succeed. 
 
Syncona is aligned with two of the premium charitable funders in UK science, 
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both 
of which are significant shareholders in our business.  We make a donation of 
0.3% of Net Asset Value to a range of charities each year. 
 
 
 
END 
 

(END) Dow Jones Newswires

January 02, 2018 04:47 ET (09:47 GMT)